Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

47.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
From Guardant Health, Inc.
Via Business Wire
Key Takeaways From Guardant Health Analyst Ratings
Via Benzinga
Analyst Expectations For Guardant Health's Future
Via Benzinga
4 Analysts Have This To Say About Guardant Health
Via Benzinga
Guardant Health: Q4 Earnings Insights
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q1 2024
GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Decoding 4 Analyst Evaluations For Guardant Health
Via Benzinga
Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
From Guardant Health, Inc.
Via Business Wire
Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday
Via Benzinga
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
The companies are working to detect colon cancer and precancerous markers in blood and/or stool. 
Via Investor's Business Daily
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
These stocks are solid buys according to the advanced AI model Claude 3, which has been touted as potentially superior to ChatGPT. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat... 
Via Benzinga
Insiders Buying Advance Auto Parts And 2 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
From Guardant Health, Inc.
Via Business Wire
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Guardant Health surpasses Q4 2023 revenue expectations, reporting $155.1 million. Precision oncology revenue is up 25% to $142.2 million. Adjusted EPS loss beats consensus. Update on Shield CRC... 
Via Benzinga
Exposures Product Safety
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Guardant Health, Inc.
Via Business Wire
3 Stocks to Buy for the Age of Personalized Medicine
Personalized medicine stocks can unlock significant growth from your portfolio. Here are three companies to consider. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.